Urokinase
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | |||
<StructureSection load='1c5w' size='340' side='right' caption='Human urokinase short chain (grey) and catalytic domain (green) complex with iodobenzine inhibitor and citrate, [[1c5w]]' scene='' > | <StructureSection load='1c5w' size='340' side='right' caption='Human urokinase short chain (grey) and catalytic domain (green) complex with iodobenzine inhibitor and citrate, [[1c5w]]' scene='' > | ||
== Function == | == Function == | ||
'''Urokinase''' (UK) is a serine protease whose principal substrate is plasminogen – the inactive zymogen of plasmin<ref>PMID:21711235</ref>. UK consists of 3 domains: ligand-binding domain and kringle and growth factor domains. Prourokinase (PUK) is the inactive zymogen of UK which becomes active by proteolytic cleavage into catalytic domain (residues 179-431) and short chain (residues 156-178). | '''Urokinase''' (UK) is a serine protease whose principal substrate is plasminogen – the inactive zymogen of plasmin<ref>PMID:21711235</ref>. UK consists of 3 domains: ligand-binding domain and kringle and growth factor domains. Prourokinase (PUK) is the inactive zymogen of UK which becomes active by proteolytic cleavage into catalytic domain (residues 179-431) and short chain (residues 156-178). | ||
| + | |||
| + | == Relevance == | ||
| + | Increased levels of UK are associated with poor prognosis in patients with breast cancer and thus is used as prognostic markers for the disease<ref>PMID:15944776</ref>. | ||
</StructureSection> | </StructureSection> | ||
== 3D Structures of urokinase == | == 3D Structures of urokinase == | ||
Revision as of 09:16, 11 December 2016
| |||||||||||
3D Structures of urokinase
Updated on 11-December-2016
References
- ↑ Carriero MV, Stoppelli MP. The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling. Curr Pharm Des. 2011;17(19):1944-61. PMID:21711235
- ↑ Han B, Nakamura M, Mori I, Nakamura Y, Kakudo K. Urokinase-type plasminogen activator system and breast cancer (Review). Oncol Rep. 2005 Jul;14(1):105-12. PMID:15944776
